Main Navigation
 
Search
Advanced Search>>
Free Newsletter
Subscribe
Unsubscribe
 
 
  
Health Headlines

Get the latest news in prevention and health matters. This feature includes daily postings and recent archives to keep you up to date on health reports and wires around the world.
Weekly Wellness
Get informed with weekly wellness facts in a diversity of health topics from prevention to fitness and nutrition.
Tips
Great tips on what you need to know about keeping healthy and active all year round.

 

Heart Disease Vaccines Show Promise

(Reuters Health) - Several vaccines are being developed to reduce heart disease risk factors, and could one day be used to help prevent heart attacks, according to a presentation here Tuesday at the Fourth Annual Conference on Vaccine Research.

Dr. Carl R. Alving of the Walter Reed Army Institute of Research in Silver Spring, Maryland, presented evidence implicating various infectious agents in the development of atherosclerosis, or hardening of the arteries, and described developments in vaccines that may reduce heart disease risk factors such as high cholesterol.

Alving noted that the fatty plaques that obstruct the arteries in atherosclerosis have been found to contain bacteria including Chlamydia, cytomegalovirus and Helicobacter pylori.

``Studies have shown that if you inject a test animal with Chlamydia, it will increase the amount of atherosclerosis that occurs,'' Alving told Reuters Health. ``If you then treat these animals with antibiotics, it will reduce the amount of atherosclerosis that forms. It has also been shown that if you vaccinate against the Chlamydia organism, you can achieve the same effect.

``The value of a vaccine against Chlamydia would be tremendously increased from a commercial and public health standpoint if atherosclerosis could be decreased,'' Alving pointed out. He mentioned that there are at least a half-dozen studies under way to determine whether Chlamydia vaccine does indeed reduce heart and blood vessel disease in humans.

AVANT Immunotherapeutics in Needham, Massachusetts has recently completed a preliminary trial of vaccine against cholesterol ester transfer protein (CETP), Alving stated. CETP is an enzyme that transfers cholesterol from high-density lipoproteins (HDL), the so-called ``good cholesterol,'' to low-density lipoproteins (LDL), also known as ``bad cholesterol.'' The vaccine boosts good cholesterol levels and reduces bad cholesterol by blocking this enzyme.

``The possibility of developing infectious disease and metabolic vaccines for atherosclerosis risk factors may be immediately on the horizon,'' Alving concluded.

Reference Source 89

For more information on how to prevent other diseases, use
PreventDisease.com's "Quick Prevention Resources".

Select a Channel